Walleye Capital’s Novartis NVS Stock Holding History

Walleye Capital’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.1M	Buy	13,734 +13,733	+1,373,300%	+$2.11M	0.01%	1426
2025 Q4	$138	Sell	1 -20,854	-100%	-$2.73M	﹤0.01%	4427
2025 Q3	$2.67M	Buy	20,855 +17,067	+451%	+$2.08M	0.01%	1365
2025 Q2	$458K	Sell	3,788 -1,370	-27%	-$154K	﹤0.01%	2716
2025 Q1	$575K	Buy	5,158 +5,038	+4,198%	+$536K	﹤0.01%	2434
2024 Q4	$11.7K	Sell	120 -29,186	-100%	-$3.11M	﹤0.01%	4568
2024 Q3	$3.37M	Buy	29,306 +25,743	+723%	+$2.92M	0.01%	1478
2024 Q2	$379K	Sell	3,563 -10,735	-75%	-$1.08M	﹤0.01%	3753
2024 Q1	$1.38M	Buy	+14,298	New	+$1.47M	﹤0.01%	2278
2018 Q3	$410K	Buy	+5,307	New	+$392K	0.19%	147

Other funds holding NVS

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Walleye Capital's NVS Position: Q1 2026 in Review

Walleye Capital increased its Novartis (NVS) stake by 1,373,300% in Q1 2026, buying an estimated $2.11M and bringing the position to 13,734 shares worth $2.1M. The position accounts for 0.01% of the portfolio, ranked #1426.

Walleye Capital first reported a position in NVS in Q3 2018 and has held it in 10 quarters since. The position peaked at $3.37M in Q3 2024. 1,591 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

Walleye Capital held 13,734 shares of Novartis worth $2.1M as of Q1 2026.
Walleye Capital bought 13,733 Novartis shares in Q1 2026, an estimated $2.11M.
Novartis made up 0.01% of Walleye Capital's portfolio in Q1 2026, its #1426 holding.
Walleye Capital first reported a position in Novartis in Q3 2018 and has held it in 10 quarters since.
Walleye Capital's Novartis position peaked at $3.37M in Q3 2024.
1,591 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.